KVUE vs PG: How Kenvue and Procter & Gamble Compare (2026)
Last updated July 2026
Short answer
PG is the larger of the two ($337.32B market cap): the incumbent the market prices for continued execution (19.50x forward earnings, beta 0.38). KVUE is the smaller challenger ($37.75B), cheaper on forward earnings (15.84x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
KVUE vs PG: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | KVUE | PG | What it tells you |
|---|---|---|---|
| Market cap | $37.75B | $337.32B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.84 | 19.50 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 23.40 | 21.21 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.44 | 0.38 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 68% of range | 24% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.56 | 6.28 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: KVUE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how KVUE and PG affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KVUE and PG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KVUE and PG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Kenvue (KVUE) do?
Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023. It owns a portfolio of iconic over-the-counter and personal-care brands organized into three segments: Self Care (Tylenol, Motrin, Sudafed, Zyrtec, Benadryl, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX), and Essential Health (Listerine, Band-Aid, Johnson's baby products, Aveeno). Kenvue sells everyday, repeat-purchase health and hygiene products through pharmacies, mass retailers, grocery, and e-commerce in markets around the world. The business makes money by leveraging strong, trusted brands and broad retail distribution to command premium pricing over private label in non-discretionary categories like pain relief, allergy care, oral care, and wound care. Many of its products are recommended by doctors and pharmacists, which reinforces brand loyalty. As a recently independent company, Kenvue is still building out standalone operations and pursuing cost efficiencies, while navigating litigation it inherited from its J&J consumer heritage. Headquartered in Summit, New Jersey.
What does Procter & Gamble (PG) do?
Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Its portfolio is organized into segments spanning fabric and home care (Tide, Ariel, Downy, Dawn, Febreze), baby, feminine, and family care (Pampers, Always, Bounty, Charmin), beauty (Olay, Pantene, Head & Shoulders, SK-II), grooming (Gillette, Venus), and health care (Crest, Oral-B, Vicks, Metamucil). P&G makes money selling these branded products through retailers, e-commerce, and other channels worldwide, relying on scale, marketing, and continual product innovation to command premium pricing and shelf space. The company deliberately pruned its portfolio over the past decade to focus on a smaller set of large, profitable, daily-use categories. Founded in 1837 and headquartered in Cincinnati, Ohio, P&G is a classic defensive blue chip and a Dividend King, prized for steady cash flow, pricing power, and an exceptionally long record of dividend increases.
KVUE vs PG: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- KVUE drivers: Portfolio of trusted, defensive brands; Standalone efficiency and margin upside.
- PG drivers: Brand strength and pricing power; Defensive, recurring demand.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. For PG, p&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives.
KVUE or PG: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KVUE if you believe its drivers more; PG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KVUE and PG guides.
KVUE vs PG: the full fundamentals
KVUE. Kenvue trades at a consumer-staples multiple, somewhat below larger, faster-growing peers, reflecting its strong brands offset by litigation overhang and an unproven standalone growth track record. The above-average dividend yield is a key anchor for income investors. The valuation embeds expectations of margin improvement and steadier organic growth as the company matures independently and resolves legal uncertainties.
PG. P&G is a high-margin, cash-rich consumer-staples leader that commands a premium valuation for its brand strength, defensiveness, and unmatched dividend record. The financial profile is steady rather than fast-growing: modest organic growth, reliable margins, and consistent capital return funded by very strong free cash flow.
Headline figures (approximate, early 2026): KVUE shows revenue (ttm) ~$15 billion, operating margin ~18%, net income (ttm) ~$1.5 billion, p/e (ttm) ~20x; PG shows revenue (ttm) ~$84 billion, operating margin ~24%, net margin ~18%, free cash flow ~$15+ billion annually.
The bottom line: KVUE vs PG
KVUE and PG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KVUE and PG exposure against your real portfolio. It is not an investment adviser.
Wondering how KVUE or PG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Kenvue with AI
Connect the broker you already use and ask Walnut's AI how KVUE fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between KVUE and PG?
+
Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023. Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is KVUE or PG the better stock?
+
Neither is universally better. PG is the larger incumbent; KVUE is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, KVUE or PG?
+
On forward P/E (as of July 2026), KVUE trades at 15.84x and PG at 19.50x, so KVUE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both KVUE and PG?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of KVUE vs PG?
+
KVUE: Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. As a young standalone company it is still proving it can execute independently and grow organically, and early results have shown uneven volume trends. Private-label competition pressures pricing in OTC and personal care, input-cost inflation hits margins, and heavy international exposure adds currency risk. Activist pressure and possible portfolio changes add uncertainty, and slow growth makes the stock sensitive to interest rates and consumer trade-down. PG: P&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives. A large share of sales comes from outside the US, exposing earnings to a strong dollar and emerging-market currency swings. Input-cost inflation (commodities, energy, transportation) can pressure margins. Private-label competition and shifting retailer dynamics, including the bargaining power of large retailers, are persistent threats. The defensive profile also means the stock can lag sharply in strong bull markets, and its premium valuation leaves little room for execution missteps.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell KVUE or PG; figures are approximate and dated (as of July 2026). Verify current data before investing.